Image Sourced ShutterStock
Market Herald logo


Be the first with the news that moves the market
  • Health160 is one of China’s top three telemedicine platforms with over 167 million users
  • Designed to help patients with weight loss, diabetes and a range of heart conditions
  • It is hoped this partnership will help the rapidly growing need for medical services in China

CardieX Limited and inHealth Medical Services have announced they have been chosen by Chinese company Health160 to collaborate on a program to deploy inHealth’s Telehealth solutions.

Described as one of China’s top three telemedicine platforms, Health160 is committed to improving healthcare across all of China by providing medical and health solutions to its 167 million registered users.

The signing of an MOU with CardieX and inHealth will be the first such agreement on the Health160 platform.

InHealth’s Telehealth solutions will provide digital and mobile tools for Chinese patients to connect online with health coaches. This is path of inHealth’s patient care management system which will be offered throughout the Health160 platform.

These solutions will be available for weight loss management, diabetes management, hypertension and overall heart health.

Telemedicine is the use of telecommunication and information technology to provide health care from a distance. It can be used to overcome distance barriers and assist in medical services in rural and third world countries.

It initially started out on the radio and telephone but now has expanded to video calling and real-time live footage.

As part of the partnership Health160 and inHealth will develop joint strategies to market inHealth’s solutions to Health106’s customer base. The companies will also test and train inHealth’s Chinese speaking health coaches to ensure seamless communication with existing Health160 users.

The program is currently in its first phase of a potentially significant commercial opportunity and long-term partnership in China.

It is hoped this technology will meet the rapidly growing need in the healthcare market while not burdening China’s overcrowded hospital system.

Please find announcement here  

CDX by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.